Wmi.usyd.edu.au

–––––––––––
• Uhlenhaut, N., Barish, G., Yu, R., Downes, M., Karunasiri, M., Liddle, C., Schwalie, P., Hübner, N., Evans, R. (2013), Insights into Negative Regulation by the Glucocorticoid Receptor from Genome-wide Profiling of Inflammatory Cistromes. Molecular Cell. 49(1), 158-171. • Jonker, J., Liddle, C., Downes, M. (2012), FXR and PXR: Potential therapeutic targets in cholestasis. The Journal of Steroid Biochemistry and Molecular Biology. 130(3-5), 147-158. • Cho H, Zhao X, Hatori M, Yu RT, Barish GD, Lam MT, Chong LW, Ditacchio L, Atkins AR, Glass CK, Liddle C, Auwerx J, Downes M, Panda S, Evans RM. Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β, Nature; 2012 Mar 29. doi: 10.1038/nature11048. • Subramaniam N, Sherman MH, Rao R, Wilson C, Coulter S, Atkins AR, Evans RM, Liddle C, Downes M. Metformin-Mediated Bambi Expression in Hepatic Stellate Cells Induces Prosurvival Wnt/β-Catenin Signaling. Cancer Prev Res (Phila). 2012 Apr;5(4):553-61. Epub 2012 Mar 9. | Professor Chris Liddle | Westmead Mil ennium Institute | Page 1 of 6 | • Vanwijngaerden, Y., Wauters, J., Langouche, L., Vander Perre, S., Liddle, C., Coulter, S., Vanderborght, S., Roskams, T., Wilmer, A., Berghe, G., Mesotten, D. Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression. Hepatology (Baltimore, Md.). 2011; 54:1741-52. • Kacevska, M., Downes, M., Sharma, R., Evans, R., Clarke, S., Liddle, C., Robertson, G. Extrahepatic Cancer Suppresses Nuclear Receptor-Regulated Drug Metabolism. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17:3170-80. • Suan, D., O'Connor, K., Booth, D., Liddle, C., Stewart, G. Voriconazole toxicity related to polymorphisms in CYP2C19. Internal Medicine Journal. 2011. p. 364-365. • Chmiel, K., Suan, D., Liddle, C., Nankivell, B., Ibrahim, R., Bautista, C., Thompson, J., Fulcher, D., Kefford, R. Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy. Journal of clinical oncology : official journal of the American Society of Clinical • Wu, A., Coulter, S., Liddle, C., Wong, A., Eastham-Anderson, J., French, D., Peterson, A., Sonoda, J. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PloS one. 2011; 6:e17868. • Jonker JW, Liddle C, Downes M. FXR and PXR: Potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol., 2011 Jul 20. [Epub ahead of print]. • Stedman, C., Downes, M., Liddle, C. Signaling Pathways in Liver Diseases: PXR and CAR. In: Signaling Pathways in Liver Diseases 2nd Ed. United States: Springer 2010. p. 333-344. • Hilmer, S., Seale, J., Le Couteur, D., Crampton, R., Liddle, C. Do medical courses adequately prepare interns for safe and effective prescribing in New South Wales public hospitals? Internal medicine journal. 2009; 39:428-34. • Jonker, J., Stedman, C., Liddle, C., Downes, M. Hepatobiliary ABC transporters: physiology, regulation and implications for disease. Frontiers in Bioscience. 2009; 14:4904-4920. | Professor Chris Liddle | Westmead Mil ennium Institute | Page 2 of 6 | • Sharma, R., Zucknick, M., London, R., Kacevska, M., Liddle, C., Clarke, S. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clinical Colorectal Cancer. 2008; 7:331-337. • Robertson, G., Liddle, C., Clarke, S. Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice. Clinical pharmacology and therapeutics. 2008; 83:894-897. • Downes, M., Liddle, C. Look who's talking: nuclear receptors in the liver and gastrointestinal tract. Cell Metabolism. 2008; 7:195-199. • Klumpen, H., Liddle, C., Gurney, H. Transporter pumps and imatinib: A cause of pharmacokinetic resistance?. Cancer Biology & Therapy. 2008; 7:416-418. • Morgan, E., Goralski, K., Piquette-Miller, M., Renton, K., Robertson, G., Chaluvadi, M., Charles, K., Clarke, S., Kacevska, M., Liddle, C., Richardson, T., Sharma, R., Sinal, C. Regulation of drug- metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metabolism and Disposition. 2008; 36:205-216. • Kacevska, M., Robertson, G., Clarke, S., Liddle, C. Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert opinion on drug metabolism & toxicology. 2008; 4:137-149. • Sharma, R., Hoskins, J., Rivory, L., Zucknick, M., London, R., Liddle, C., Clarke, S. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clinical Cancer Research. 2008; 14:817-825. • Sharma, R., Kacevska, M., London, R., Clarke, S., Liddle, C., Robertson, G. Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies. British Journal of Cancer. • Liddle, C. Mass in the Liver. In: Gastroenterology and Hepatology: A Clinical Handbook. Sydney: • George, J., Liddle, C. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Molecular Pharmaceutics. 2008; 5:49-59. • Sharma, R., Koller, L., Barclay, P., Liddle, C. Evaluation of the off-label usage of rituximab in a large teaching hospital in New South Wales. Internal medicine journal. 2007; 37:569-571. • Liddle, C., Stedman, C. Hepatic Metabolism of Drugs. In: The Textbook of Hepatology: From Basic Science to Clinical Practice. United States: Blackwell Publishing Ltd 2007. p. 241-249. | Professor Chris Liddle | Westmead Mil ennium Institute | Page 3 of 6 | • Charles, K., Rivory, L., Brown, S., Liddle, C., Clarke, S., Robertson, G. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12:7492-7 • Stedman, C., Liddle, C., Coulter, S., Sonoda, J., Alvarez, J., Evans, R., Downes, M. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103:11323-8 • Sharma, R., Koller, L., Liddle, C., Barclay, P. Retrospective evaluation of the use of rituximab in a renal transplant population. Immunology and Cel Biology. 2006; 84:A11-A11 • Coombes, J., Mreich, E., Liddle, C., Rangan, G. Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney international. 2005; • Esteban, L., Fong, C., Amr, D., Cock, T., Allison, S., Flanagan, J., Liddle, C., Eisman, J., Gardiner, E. Promoter-, cel -, and ligand-specific transactivation responses of the VDRB1 isoform. Biochemical and biophysical research communications. 2005; 334:9-15. • Sonoda, J., Chong, L., Downes, M., Barish, G., Coulter, S., Liddle, C., Lee, C., Evans, R. Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102:2198-203. • Stedman, C., Liddle, C., Coulter, S., Sonoda, J., Alvarez, J., Moore, D., Evans, R., Downes, M. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proceedings of the National Academy of Sciences of the United States of | Professor Chris Liddle | Westmead Mil ennium Institute | Page 4 of 6 | • Wong, M., Balleine, R., Collins, M., Liddle, C., Clarke, C., Gurney, H. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clinical pharmacology and • Sud, A., Hui, J., Farrell, G., Bandara, P., Kench, J., Fung, C., Lin, R., Samarasinghe, D., Liddle, C., McCaughan, G., George, J. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology (Baltimore, Md.). 2004; 39:1239-47. • Coverdale, S., Khan, M., Byth, K., Lin, R., Weltman, M., George, J., Samarasinghe, D., Liddle, C., Kench, J., Crewe, E., Farrell, G. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. The American journal of gastroenterology. 2004; • Stedman, C., Robertson, G., Coulter, S., Liddle, C. Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice. The Journal of biological • Mesotten, D., Van den Berghe, G., Liddle, C., Coulter, S., McDougal , F., Baxter, R., Delhanty, P. Growth hormone modulation of the rat hepatic bile transporter system in endotoxin-induced cholestasis. Endocrinology. 2003; 144:4008-17. • Robertson, G., Field, J., Goodwin, B., Bierach, S., Tran, M., Lehnert, A., Liddle, C. Transgenic mouse models of human CYP3A4 gene regulation. Molecular pharmacology. 2003; 64:42-50. • Coverdale, S., Samarasinghe, D., Lin, R., Kench, J., Byth, K., Khan, M., Crewe, E., Liddle, C., George, J., Farrell, G. Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression. The American journal of gastroenterology. 2003; 98:1384-90. • Liddle, C., Robertson, G. Predicting inductive drug-drug interactions. Pharmacogenomics. 2003; | Professor Chris Liddle | Westmead Mil ennium Institute | Page 5 of 6 | • Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J (2002). NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. • Hui J.M., George J., Liddle C., Lin R., Samarasinghe D., Crewe E., Farrell G.C. (2002) Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance. Am J Gastroenterol.97:1003-1009. • Spurdle AB, Goodwin B, Hodgson E, Hopper J.L, Chen X, Purdie DM, McCredie MRE, Giles GG, Chenevix-Trench G, Liddle C. (2002). The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. • Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, Liddle C, Samarasinghe D, George J (2002). Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of • Chitturi S, Weltman M, Farrell GC, McDonald D, Liddle C, Samarasinghe D, Lin R, Abeygunasekera S, George J (2002). HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology36:142-149. • Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, Byth K, George J (2002) Genotype- specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol • Goodwin B, Hodgson E, D’Costa DJ, Robertson GR, Liddle C (2002) Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol62:359-365. • Liddle C, Goodwin B (2002) Regulation of hepatic drug metabolism: role of the nuclear receptors • Graudins A, Dowsett RP, Liddle C (2002) The toxicity of antidepressant poisoning: is it changing? A comparative study of cyclic and newer serotonin-specific antidepressants. Emerg Med • Farrell GC, Liddle C. (2002) Drugs and the liver updated. Semin. Liver Dis. 22:109-113. | Professor Chris Liddle | Westmead Mil ennium Institute | Page 6 of 6 |

Source: http://www.wmi.usyd.edu.au/ourpeople/Documents/Publications/ChrisLiddle.pdf